Internal Medicine

The IMPLANT 2 trial of nolasiban showed a significant increase in the rates of ultrasound-confirmed pregnancy at 10 weeks as well as live births.

Just 1 of 72 resident physicians surveyed at a North Carolina medical school had ever prescribed PrEP to a patient at high risk of contracting HIV.

Recent studies questioned the benefits of second-generation antipsychotics, prompting researchers to reassess the risks of tardive dyskinesia from the use of first- and second-generation antipsychotics.

Research indicates that influenza vaccine effectiveness was low but effective in preventing influenza-related hospitalization during the 2016-2017 flu season in Canada.

Investigators report the first real-world data on the safety and effectiveness of G/P for patients on opioid substitution therapy within the German Hepatitis C-Registry.

Keith Kaye, MD, MPH discusses the current successes and challenges in addressing multidrug-resistant infections, as well as expectations for how recommendations will change in the future.

Investigators find school-located influenza vaccination increased coverage and decreased school absence and influenza hospitalization.

In a Meet-the-Professors session at ID Week 2018, experts addressed strategies to check for drug-drug interactions, direct-acting antivirals for special populations, and the management of hepatitis C virus infection for persons who inject drugs.

Individuals with HIV who have been detained at the US border are far more likely to be released having had some consultation about their health and steps to improve their outlook compared with those who were detained several years ago.

Originally approved by the FDA in 2006, the vaccine prevents certain cancers and diseases caused by the 9 types of HPV covered by the vaccine—an expansion from its originally-approved prevention of 4 different types.

Investigators analyzed data from PrEP-eligible patients at the New York City Health + Hospital/Bellevue which showed that women and minority patients were less likely to be prescribed PrEP for HIV prevention.

Roche's investigative drug could become the first single-dose oral antiviral approved for the US market in December.

Community-onset cases still hovered around 45% of the annual cases, with the remainder being infections that developed once patients had been admitted to the hospital.

An oral influenza vaccine tablet protects against virus as well or better than an injectable quadrivalent vaccine in phase 2 trial.

Race and sex can play a role in the annual BMI gain for patients with HIV who are receiving certain antiretroviral therapy combinations.

In review of US-based infections during the 2016 outbreak, investigators found more telling indicators of the virus are patients' proximity to other infected patients, and their desire to be tested.

An intervention of scheduling an appointment and contacting the patient successfully increased re-engagement among patients with HIV who had not had a primary care visit in the previous 6 months.

XYOSTED's approval comes nearly a year following Antares first received a Complete Response Letter from the FDA for its application.

Investigators stressed the importance of culturally competent care for patients with dementia and support for their caregivers.

Less than one-third received both influnza and Tdap vaccination during their pregnancies, citing limited understanding or assurance of their benefits and safety.

In response to the evidenced connection between pediatric asthma development and air pollution exposure, investigators have sought out association indicators as early as in utero.

Female sex, previous gastrointestinal, and non-gastrointestinal comorbidities are associated with C difficile infection in women with UTIs, study finds.

A comparative study found that online prevention programs are just as effective and have higher participation rates compared to in-person programs.

Pivotal clinical trial costs increased if more patients were needed to document treatment benefit, if active drug comparators were used, or to measure clinical end points rather than a change in a surrogate outcome.

Lucia Novak discusses the importance of testing for cardiovascular outcomes of diabetes treatments and compares the cardiovascular effects of several diabetes drugs.